Effect of tumor CD276 expression on infiltrating immune cells and clinicopathological features of prostate cancer

BackgroundAdvanced prostate cancer (PCa) is often resistant to immunotherapy. In this study, we examined the role of CD276 in mediating immunotherapeutic effects through changes in immune cell infiltration.MethodsUsing transcriptomic and proteomic analyses, CD276 was identified as a potential target for immunotherapy. Subsequent in vivo and in vitro experiments confirmed its role as a potential mediator of immunotherapeutic effects.ResultsMulti-omic analysis suggested that CD276 was identified as a key molecule regulating the immune microenvironment (IM). In vivo experiments revealed that CD276 knockdown was found to enhance CD8(+) T cell infiltration into the IM. Immunohistochemical analysis of PCa samples further confirmed the same findings.ConclusionCD276 was found to inhibit the enrichment of CD8+ T cells in PCa. Thus, CD276 inhibitors may be potential targets for immunotherapy.

Automated summary

Through transcriptomic and proteomic analyses, CD276 was identified as a potential target for immunotherapy. In vivo and in vitro experiments confirmed its role in mediating immunotherapeutic effects. CD276 was found to inhibit the enrichment of CD8+ T cells in prostate cancer, suggesting that CD276 inhibitors may be potential targets for immunotherapy.